Moberg Pharma Regains Rights to Emtrix® in Certain EU Markets

STOCKHOLM--()--Regulatory News:

Moberg Pharma AB (STO:MOB) today announced that it has reached an agreement with its partner Meda to regain rights to Emtrix® in certain EU markets where the nail product has not yet been launched, including UK and Poland.

Moberg Pharma and Meda have agreed to amend their existing license and distribution agreement so Moberg regains rights to the nail product in certain EU markets. This includes UK, Poland, the Chech Republic and the Baltic countries. The two companies maintain their partnership in the remaining thirteen markets where the product has been launched under the brand names Naloc® and Nalox® and reached a leading or top 3 position in the majority of those markets.

“I am very pleased that we jointly agreed to focus our partnership on the majority of markets where it has been successful. We are evaluating options to launch by ourselves or through other distributors in the now released markets to further leverage the potential of Emtrix® in Europe” said Peter Wolpert, CEO of Moberg Pharma AB.

About this information Moberg Pharma discloses this information pursuant to the Swedish Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 8.00 am (CET) on November 10, 2015.

About Emtrix® and nail disease, www.emtrix.com

Emtrix is a topical treatment used to treat nail disease. Launched in late 2010, it quickly became the market leader in the Nordics and recently also the best-selling product in its category in the U.S. The international launch is under way via a proprietary sales organization in the U.S. and ten partners that hold rights for 50 markets, including the major EU markets, China, Turkey and Russia. Emtrix is a prescription-free, over-the-counter product sold under the names Kerasal Nail®, Naloc™/Nalox™ and Emtrix®. Safety and efficacy have been demonstrated in several clinical studies including more than 600 patients. Emtrix has a unique and rapid mechanism of action which brings visible improvements within 2-4 weeks of treatment. Nail fungus is the most common nail disease. The condition afflicts approximately 10 percent of the population and is more common among the elderly. It is generally recognized that there is a need for new efficacious and safe topical treatments.

About Moberg Pharma, www.mobergpharma.com

Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with OTC sales operations in the U.S. and a distributor network in more than 40 countries. The company’s portfolio includes the OTC brands Kerasal®, Kerasal Nail®, Balmex®, Domeboro®, Jointflex®, Vanquish®, and Fergon®. Kerasal Nail®(Emtrix®or Nalox™ in certain markets) is a leading OTC treatment of nail disorders in the U.S., Canada and several EU markets and is currently being launched in Southeast Asia. The company is growing organically as well as through acquisitions. Internal development programs focus on innovative drug delivery of proven compounds and include two clinical stage assets, MOB-015 (onychomycosis) and BUPI (pain management in oral mucositis). Moberg Pharma has offices in Stockholm and New Jersey and the company’s shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB).

This information was brought to you by Cision http://news.cision.com

Contacts

Moberg Pharma
Peter Wolpert, CEO
Phone: +46 (0)70 - 735 71 35
E-mail: peter.wolpert@mobergpharma.se
or
Anna Ljung, CFO
Phone: +46 (0)70 – 766 60 30
Email: anna.ljung@mobergpharma.se

Contacts

Moberg Pharma
Peter Wolpert, CEO
Phone: +46 (0)70 - 735 71 35
E-mail: peter.wolpert@mobergpharma.se
or
Anna Ljung, CFO
Phone: +46 (0)70 – 766 60 30
Email: anna.ljung@mobergpharma.se